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Hairy cell leukemia (HCL) is a distinct
clinicopathologic entity that responds well
to purine analogs but is sometimes diffi-
cult to differentiate from HCL-like disor-
ders (eg, splenic marginal zone lym-
phoma and HCL variant). We recently
identified the BRAF-V600E mutation as
the disease-defining genetic event in HCL.
In this study, we describe a new, simple,
and inexpensive test for genetics-based
diagnosis of HCL in whole-blood samples
that detects BRAF-V600E through a sensi-
tive allele-specific PCR qualitative assay
followed by agarose-gel electrophoresis.
This approach detected BRAF-V600E in
all 123 leukemic HCL samples investi-
gated containing as few as 0.1% leukemic
cells. BRAF-V600E was detected at differ-
ent time points during the disease course,
even after therapy, pointing to its pivotal
role in HCL pathogenesis and mainte-
nance of the leukemic clone. Conversely,
115 non-HCL chronic B-cell neoplasms,
including 79 HCL-like disorders, were in-
variably negative for BRAF-V600E. This
molecular assay is a powerful tool for
improving the diagnostic accuracy in HCL.
(Blood. 2012;119(1):192-195)
Introduction
Hairy cell leukemia (HCL) is a distinct entity usually characterized
by splenomegaly (without lymphadenopathy), pancytopenia, and
infiltration of BM, spleen, and liver by leukemic B cells with
“hairy” appearance. In contrast to other chronic B-cell leukemias,
HCL cells circulate at low percentages in the blood,1 and exhibit
distinct functional features and gene expression profile.2,3
HCL diagnosis relies on morphologic and immunophenotypic
criteria1-4 that usually allow its distinction from HCL-like disorders
of the 2008 World Health Organization classification, that is,
splenic marginal zone lymphoma (SMZL) and splenic lymphoma/
leukemia unclassifiable (SLLU; including HCL variant [HCL-v]).5
A correct diagnosis is critical because purine analogs (pentostatin
and cladribine) are highly effective only in HCL.4
The most problematic cases can be diagnosed using annexin-A1
immunostaining,6-8 which we previously reported to be highly
sensitive and specific for HCL among B-cell lymphomas.6 How-
ever, because annexin-A1 is also expressed by myeloid and
T cells,6 this immunohistochemical staining may be difficult to
interpret in BM biopsies with low percentages of HCL cells.
Moreover, immunocytochemistry for annexin-A1 is not readily
applicable to routine hematologic samples, such as peripheral
blood or diluted BM aspirate (because of dry tap), that are also
usually poor in HCL cells and rich in neutrophils and T cells.
An ideal solution would be a sensitive and specific test for a
genetics-based diagnosis of HCL. We recently identified BRAF-
V600E as the HCL-defining genetic lesion (present in all HCL
cases, absent in other B-cell neoplasms)9 by Sanger sequencing of
BRAF exon 15. However, this technique required  30% leukemic
cells for reliably detecting a clonal heterozygous mutation. Thus,
the rare HCL cells typically present in the blood of most patients
had to be purified through cell sorting,9 a laborious procedure not
amenable to a routine diagnostic setting.
Aims of this study were: (1) to develop a sensitive, easy, and
inexpensive test for the routine clinical diagnosis of HCL in blood
samples, based on BRAF-V600E detection by allele-specific PCR
(AS-PCR) followed by conventional agarose-gel electrophoresis;
and (2) to assess the diagnostic accuracy of this test in a large
cohort of HCL and HCL-like disorders.
Methods
Tumor samples
We studied 117 HCL patients: 96 before therapy and 21 after therapy, all
with detectable disease (at least 0.1% leukemic cells). We also investigated
16 HCL patients after therapy in complete flow cytometric remission
( 0.1% leukemic cells), 112 patients with other B-cell neoplasms
(61 SMZL; 18 SLLU, including 11 HCL-v; 31 chronic lymphocytic
leukemias [CLL]; 5 unclassifiable CD5-negative mature B-cell neoplasms),
and 9 healthy blood donors (see supplemental Methods for details, available
on the Blood Web site; see the Supplemental Materials link at the top of the
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online article). Samples from 23 HCL patients and 38 non-HCL patients
were previously reported.9 Diagnosis of HCL and non-HCL tumors
conformed to the WHO 2008 classification.1,5 Patients gave verbal or
written consent for the analysis of their sample material in accordance with
the Declaration of Helsinki, and the study was approved by the local ethics
committee at Perugia University.
Figure 1. Flow cytometry and AS-PCR assays in HCL and HCL-like disorders. (Top panel) Flow cytometry dot plots of a whole-blood sample subjected to RBC lysis from a
representative HCL patient (top graphs) and of purified peripheral blood leukemic cells from a representative patient with HCL-v (bottom graphs). HCL cells (CD19/CD25 red
events in the top right panel) represent 2% of all nucleated cells (CD45 black events in the top left panel). HCL-v cells (CD19/CD25 and CD19/CD103 red events in the
bottom left and right panels, respectively) represent 92% of all cells. (Bottom panel) Conventional agarose-gel electrophoresis of samples from 13 HCL patients (top panels;
12 pretreatment, 1 with residual disease after treatment) and 16 HCL-like patients (bottom gels; 6 SLLU, 10 SMZL), after AS-PCR for the mutant allele (1st and 3rd gel from the
top) and for the wild-type allele (2nd and 4th gel from the top). In the top-most gels, serial dilutions of mutated and wild-type alleles (from 3.1% to 0% muted alleles) are also
included to show the analytical sensitivity of the mutant AS-PCR ( 0.1% mutated alleles). All HCL samples gave rise to a mutant BRAF-V600E band as opposed to none of the
HCL-like samples. One of the latter (SMZL case 30), which did not give rise to the wild-type band either, was not evaluable in this particular experiment (shown on purpose), but
on repetition turned out to be evaluable (ie, strong wild-type band) and negative for BRAF-V600E (ie, mutant band not visible). To facilitate the visualization of the results, the gel
lane of HCL case 13 was repositioned in the 2 top gels and the gel lane of the 50-bp DNA ladder was repositioned in the 2 bottom gels.
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Qualitative AS-PCR for BRAF-V600E
Briefly, the assay consists of 2 PCRs sharing the same reverse primer
(5-GTAACTCAGCAGCATCTCAGGG-3) but differing for the forward
primer, which is complementary to either the wild-type (T) or the mutated
(A) base causing the V600E replacement. Forward primers were: 5-
AGGTGATTTTGGTCTAGCTACAGA-3 (mutated base in bold) and
5-AGGTGATTTTGGTCTAGCTACAGT-3 (wild-type base in bold).
After mutant AS-PCR, detection of a band on agarose-gel electrophoresis
indicates the presence of the mutation. Conversely, absence of the band
indicates lack of the mutation as long as the wild-type AS-PCR (positive
control) gives a readily visible product (see supplemental Methods for
details).
Results and discussion
We first assessed the analytical sensitivity of our AS-PCR in serial
dilutions of DNA from a BRAF-V600E homozygous sample with
DNA from a BRAF wild-type sample, and established the lower
detection limit to be 0.1% of mutant alleles (Figure 1), correspond-
ing to 0.2% of diploid tumor cells harboring a clonal heterozygous
BRAF-V600E mutation (or 0.1% if the mutation is homozygous).
We then analyzed samples from 123 HCL patients (101 before
treatment; 22 with residual or relapsing disease) and all tested
positive (100% diagnostic sensitivity; Table 1, Figure 1), including
23 samples previously known to harbor BRAF-V600E by Sanger
sequencing.9 Notably, among the newly reported 94 HCL cases,
24 (17 before treatment, 7 after treatment) had only 0.1% to 5%
leukemic cells and 11 were analyzed after the onset of the disease
(range 1-26 years).
These findings demonstrate the excellent analytical and diagnos-
tic sensitivity of our test. They also confirm and extend our
previous report that BRAF-V600E occurs and persists over the
disease course in virtually all HCL cases,9 further supporting the
view that BRAF-V600E represents the key pathogenetic event in
HCL and therefore a new therapeutic target. Indeed, persistence of
BRAF-V600E at partial remission or relapse after conventional
therapy establishes the rationale for using active BRAF inhibitors10
in this setting. Our test may also serve as a new tool (in addition to
IHC, flow cytometry, and Ig gene rearrangement analysis11,12) to
assess minimal residual disease (MRD) after therapy, although the
clinical relevance of MRD in HCL remains unclear.12
We next evaluated the diagnostic specificity of our test by
analyzing blood samples from 9 healthy donors and 16 HCL
patients in complete flow cytometric remission ( 0.1% leukemic
cells) after therapy, and all tested negative (Table 1, Figure 1).
Specificity was also assessed in 115 patients with non-HCL chronic
B-cell neoplasms. Because absence9 or very rare occurrence13-17 of
BRAF-V600E has been already reported in several B-cell tumors,
we focused on HCL-like disorders that, being rare, have been so far
poorly investigated. Therefore, we included, among the 115 cases,
79 patients with SMZL and SLLU, of which 65 previously
unreported.9 Notably, all 112 cases tested negative (Table 1, Figure
1), showing a 100% diagnostic specificity of our assay and further
confirming in a larger patient series the absence of BRAF-V600E in
HCL-like disorders. Considering that 37 HCL-like cases had
 40% neoplastic cells and that our test can detect 0.1% mutant
alleles, these data also argue against the presence of small
BRAF-V600E–mutated subclones (down to 0.5% of a whole
leukemic population representing  40% of the sample) in HCL-
like disorders. This finding further supports the concept that,
among B-cell lymphomas and leukemias, BRAF-V600E is the
genetic lesion defining HCL.9 Although we have collectively
analyzed 99 HCL-like disorders (SMZL and SLLU, the latter
including 19 HCL-v) without finding BRAF-V600E in any of them
(this article and Tiacci et al9), we cannot exclude that this mutation
may be rarely found in these and other B-cell neoplasms if a larger
number of cases is investigated.
Our diagnostic test is especially useful for patients with a low
tumor burden in the blood (as typically occurs in HCL) or BM. In
this setting, it appears superior to annexin-A1 immunostaining,
which may be difficult to interpret (because of annexin-A1
expression by myeloid and T cells) unless a technically demanding
double staining for annexin-1 and a B-cell marker (eg, PAX5) is
performed. Our gel-based AS-PCR is considerably more sensitive
than a recently described high-resolution-melting analysis (HRMA)–
based PCR, which was applied to fewer HCL samples (n  48)
containing more ( 10%) leukemic cells.18 Notably, our test
detected BRAF-V600E in all blood samples having  10% HCL
cells (37 of 88 samples; 27 before therapy; 10 after therapy) and
does not require the expensive instrumentation needed for HRMA.
In conclusion, our sensitive, simple, and reliable assay confirms
the constant presence of BRAF-V600E in HCL (as also reported in
Boyd et al18 and Arcaini et al19) and its absence in HCL-like
disorders, and adds to the already available armamentarium for
improving the diagnostic accuracy in HCL and HCL-like disorders.
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Blood, pretreatment 1%-90% 81 81 (100)
Blood, MRD 0.1%-13% 10 (100)
Blood, complete
remission
Not detectable 16 0 (0)
BM biopsies 30%-80% 14 14 (100)
Purified leukemic cells  90% 17 17 (100)
Splenic marginal zone
lymphoma
2%-97% 61 0 (0)
Splenic lymphoma/leukemia
unclassifiable
15%-97% 18* 0 (0)
Chronic lymphocytic
leukemia
18%-98% 31 0 (0)
CD5-negative mature B-cell
neoplasm unclassifiable
15%-97% 5 0 (0)
Healthy blood donors Not present 9 0 (0)
AS-PCR indicates allele-specific PCR; HCL, hairy cell leukemia; and MRD,
minimal residual disease.
*Including 11 HCL variants.
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